Drug class
BRAF kinase inhibitor; targeted antineoplastic small molecule
Mechanism of action
Selectively inhibits BRAF V600-mutant kinase activity and downstream MAPK signalling. It is used in combination regimens with MEK or EGFR inhibition to limit pathway reactivation and improve antitumour activity.
General use cases
- In combination with binimetinib for adults with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation
- In combination with cetuximab for adults with metastatic colorectal cancer with a BRAF V600E mutation after prior therapy
- Additional tumour-specific combinations and indications depend on the current product label and jurisdiction
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
